Royal Bank Of Canada Issues Positive Forecast for Becton, Dickinson and Company (NYSE:BDX) Stock Price

Becton, Dickinson and Company (NYSE:BDX) had its target price upped by research analysts at Royal Bank Of Canada from $180.00 to $190.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a “sector perform” rating on the medical instruments supplier’s stock. Royal Bank Of Canada’s price objective would indicate a potential upside of 3.18% from the stock’s current price.

BDX has been the subject of several other reports. Piper Sandler raised their price target on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, August 7th. UBS Group started coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a “buy” rating and a $190.00 target price on the stock. TD Cowen raised their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. Jefferies Financial Group reiterated a “buy” rating and set a $210.00 target price on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Finally, Citigroup restated a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $185.67.

Becton, Dickinson and Company Stock Up 0.3%

Becton, Dickinson and Company stock traded up $0.57 on Thursday, hitting $184.15. 245,511 shares of the stock traded hands, compared to its average volume of 2,678,070. The business’s fifty day simple moving average is $156.55 and its 200 day simple moving average is $161.69. The firm has a market cap of $50.74 billion, a P/E ratio of 55.38, a price-to-earnings-growth ratio of 12.79 and a beta of 0.19. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.84%. The business had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter in the prior year, the company earned $3.68 earnings per share. The business’s revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the sale, the executive vice president owned 13,172 shares of the company’s stock, valued at $1,918,633.52. The trade was a 7.71% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 7,627 shares of company stock worth $1,206,549 in the last 90 days. 0.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Imprint Wealth LLC bought a new position in Becton, Dickinson and Company in the 3rd quarter worth approximately $25,000. SHP Wealth Management purchased a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at about $26,000. Meeder Asset Management Inc. lifted its position in shares of Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 102 shares in the last quarter. Main Street Group LTD bought a new position in Becton, Dickinson and Company during the first quarter valued at approximately $29,000. Finally, Bell Investment Advisors Inc purchased a new position in Becton, Dickinson and Company during the 2nd quarter valued at approximately $29,000. Institutional investors own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.